New immunotherapy combo tested for advanced cancers
NCT ID NCT07173244
First seen Nov 01, 2025 · Last updated Jun 19, 2026 · Updated 30 times
Summary
This real-world study will look at how safe and effective adebrelimab-based combinations are for people with advanced solid tumors, including lung and gastrointestinal cancers. Researchers will track side effects and treatment outcomes in 300 participants across multiple centers. The goal is to gather practical data on how these regimens work outside of strict clinical trial settings.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Adebrelimab (an immunotherapy drug)
What this could lead to
If successful, this could show that adebrelimab combinations are safe and effective for treating advanced solid tumors, potentially offering a new treatment option.
What could go wrong
This is an observational study, not a controlled trial, so results may be less definitive. Side effects from immunotherapy can be serious, and benefits may vary widely among patients.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.